InsiderSignal.AI

InsiderSignal.ai

KNSA - Kiniksa Pharmaceuticals International, Plc

Insider Sale by Patel Sanj K (COB, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Today, Patel Sanj K, serving as COB, CEO at Kiniksa Pharmaceuticals International, Plc (KNSA), sold 48,565 shares at $54.02 per share, for a total transaction value of $2,623,481.00. Following this transaction, Patel Sanj K now holds 237,763 shares of KNSA.

This sale represents a 17.00% decrease in Patel Sanj K's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, May 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, May 1, 2026, meaning the disclosure happened on the same day as the trade.

Kiniksa Pharmaceuticals International, Plc operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Patel Sanj K

COB, CEO

Sanj K. Patel is the Chairman and Chief Executive Officer (CEO) of Kiniksa Pharmaceuticals International, Plc (KNSA), a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapies for patients with debilitating diseases and unmet medical needs.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel)[[3]](https://www.zoominfo.com/p/Sanj-Patel/894739082)[[5]](https://www.marketscreener.com/insider/SANJ-PATEL-A0NFO8/) He founded Kiniksa in 2015 and took the company public on NASDAQ in May 2018.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel)[[4]](https://boston.citybuzz.co/article/357084/syros-pharmaceuticals-appoints-sanj-k-patel-to-its-board-of-directors)[[5]](https://www.marketscreener.com/insider/SANJ-PATEL-A0NFO8/) Patel brings over 25 years of biopharmaceutical experience, including founding Synageva BioPharma in 2008, where he served as President and CEO, leading its $9.5 billion acquisition by Alexion Pharmaceuticals in 2015 after developing and gaining approval for Kanuma®, the first therapy for Lysosomal Acid Lipase Deficiency.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel)[[2]](https://ir.biocryst.com/news-releases/news-release-details/sanj-k-patel-appointed-biocrysts-board-directors)[[4]](https://boston.citybuzz.co/article/357084/syros-pharmaceuticals-appoints-sanj-k-patel-to-its-board-of-directors) Previously at Genzyme Corporation (1999-2008), he led U.S. sales, marketing, and commercial operations for key products like Myozyme®, Cerezyme®, Fabrazyme®, and Aldurazyme®, and directed clinical operations resulting in Fabrazyme®'s FDA approval in 2003.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel) Earlier roles were at Burroughs Wellcome, Hoechst Marion Roussel, and Fujisawa/Otsuka.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel) He holds a BSc with Honors in Biotechnology from the University of the South Bank, London, management studies from Ealing College, and pharmacology research from the Wellcome Foundation.[[1]](https://theorg.com/org/kiniksa-pharmaceuticals/org-chart/sanj-k-patel)

View full insider profile →

Trade Price

$54.02

Quantity

48,565

Total Value

$2,623,481.00

Shares Owned

237,763

Trade Date

Friday, May 1, 2026

Today

SEC Filing Date

Friday, May 1, 2026

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning KNSA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6108760

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime